Johns Hopkins University

Running trials

• Not yet recruiting

  Safety Study of XT-150 in Participants With ALS

  NCT06704347· PHASE1· Source

• Not yet recruiting

  Brain Imaging of DSP-2342

  NCT07850102· PHASE2· Source

• Recruiting

  Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

  NCT07665372· Source

• Not yet recruiting

  Can Mindfulness and Virtual Reality Reduce Stress in Young Adults With Type 1 Diabetes?

  NCT07793097· Source

• Recruiting

  Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services

  NCT07438041· Source

• Not yet recruiting

  WATER IV PCa (AS Sub-study)

  NCT07650448· Source

• Recruiting

  PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

  NCT07550517· PHASE2· Source

• Recruiting

  An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

  NCT06996652· PHASE2· Source

• Enrolling by invitation

  Stimulant and Polysubstance Use, Inflammation, and Sex Effects on Myocardial Disease in HIV

  NCT07461350· Source

• Recruiting

  PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

  NCT07232069· PHASE3· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· PHASE3· Source

• Recruiting

  Screen2Prevent (S2P)

  NCT07728123· Source

• Recruiting

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

  NCT07644559· PHASE2· Source

• Recruiting

  Implementation of a Beauty Salon-Based Strategy for Blood Pressure Management Among Women

  NCT07042386· Source

• Recruiting

  Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

  NCT07621718· PHASE3· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· PHASE3· Source

• Recruiting

  Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

  NCT07226453· PHASE2· Source

• Recruiting

  Precision Radiotherapy Enabled by Molecular MRI

  NCT07512154· Source

• Recruiting

  Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

  NCT07497399· PHASE2· Source

• Recruiting

  A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

  NCT07143968· PHASE2· Source

• Recruiting

  EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  NCT07287670· PHASE2· Source

• Recruiting

  Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

  NCT07297979· PHASE1· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· PHASE3· Source

• Recruiting

  Trial of Food Is Medicine Approaches for Obesity Treatment in Adults With Food Insecurity

  NCT07396805· Source

• Recruiting

  Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar

  NCT07337590· Source

• Recruiting

  Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

  NCT07059091· PHASE2· Source

• Recruiting

  Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

  NCT07389590· PHASE4· Source

• Recruiting

  CF Wellness Program

  NCT07071324· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· PHASE3· Source

• Recruiting

  Addressing Hypertension Care in Africa Program

  NCT06986590· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

  NCT07227454· PHASE3· Source

• Recruiting

  Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

  NCT07195591· PHASE3· Source

• Recruiting

  Exercise in Prostate Cancer

  NCT06165302· Source

• Recruiting

  A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  NCT07008118· PHASE1· Source

• Recruiting

  Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

  NCT06847399· PHASE2· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· PHASE3· Source

• Recruiting

  Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

  NCT06188741· PHASE2· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· PHASE3· Source

• Recruiting

  Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

  NCT06950385· PHASE3· Source

• Recruiting

  Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06995677· PHASE2· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· PHASE3· Source

• Recruiting

  A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  NCT07020221· PHASE1 PHASE2· Source

• Recruiting

  Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

  NCT05730283· PHASE2· Source

• Recruiting

  Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

  NCT06563895· PHASE3· Source

• Recruiting

  Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

  NCT06683092· Source

• Recruiting

  Myofascial Dysfunction in Post Stroke Shoulder Pain

  NCT06718413· PHASE2· Source

• Recruiting

  Embryonal Tumor With Multilayered Rosettes

  NCT06861244· PHASE2· Source

• Recruiting

  Rilonacept in Subjects With Cardiac Sarcoidosis

  NCT06660732· PHASE2· Source

• Recruiting

  SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

  NCT06389097· Source

• Active, not recruiting

  WATER IV Prostate Cancer

  NCT06651632· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers11 recruiting
• Lung cancer9 recruiting
• HIV8 recruiting
• Prostate cancer8 recruiting
• Cystic fibrosis6 recruiting
• Pancreatic cancer6 recruiting
• Heart failure5 recruiting
• Colorectal cancer4 recruiting
• Obesity4 recruiting
• Sarcoma4 recruiting
• Type 1 diabetes4 recruiting
• ALS (motor neurone disease)3 recruiting
• Alzheimer disease3 recruiting
• Coronary artery disease3 recruiting
• Head and neck cancer3 recruiting
• High blood pressure3 recruiting
• Huntington's disease3 recruiting
• Macular degeneration3 recruiting
• Multiple sclerosis3 recruiting
• Stroke3 recruiting
• Acute myeloid leukemia2 recruiting
• Amyloidosis2 recruiting
• Bladder cancer2 recruiting
• Chronic kidney disease2 recruiting
• COPD2 recruiting
• Endometrial cancer2 recruiting
• Epilepsy2 recruiting
• Frontotemporal dementia2 recruiting
• Glioblastoma2 recruiting
• Melanoma2 recruiting
• Parkinson disease2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Atrial fibrillation1 recruiting
• Cervical cancer1 recruiting
• Crohn's disease1 recruiting
• Depression1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and esophageal cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Schizophrenia1 recruiting
• Sickle cell disease1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  OnTrackCF: Engagement, Feasibility, and Acceptability Study

  NCT07031323· Source

• Completed

  A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

  NCT06159725· PHASE1 PHASE2· Source

• Completed

  AdapTive Personalized Dietitian coacHing, Messaging and pRoduce prescrIption to improVE Healthy Dietary Behaviors

  NCT06257550· Source

• Completed

  Adaptation and Feasibility of the Community-Based Anxiety Program Tailored for Autism (CAPTA)

  NCT06046170· Source

• Completed

  Analysis of Cellular Kinases and Aging in PBMCs and Colorectal Tissue

  NCT06132386· Source

• Completed

  Health Outcomes of Parents With Cystic Fibrosis

  NCT05829694· Source

• Completed

  Patient Centered Mobile Health Technology Enabled Atrial Fibrillation Management

  NCT05400837· Source

• Recruiting

  A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT05442567· PHASE3· Source

• Completed

  Impact of a Corrie Cardiac Rehabilitation Program

  NCT05238103· Source

• Completed

  Community Active and Healthy Families

  NCT04414553· Source

• Completed

  Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

  NCT05284617· PHASE2· Source

• Completed

  A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

  NCT05453578· PHASE1 PHASE2· Source

• Completed

  Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

  NCT05633407· PHASE2· Source

• Completed

  Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors

  NCT05383872· Source

• Completed

  A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

  NCT05360680· PHASE1· Source

• Completed

  A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

  NCT05375903· PHASE1· Source

• Completed

  Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

  NCT04965597· PHASE2· Source

• Completed

  MEMORI Corps: Activity-based Companion Care for Dementia

  NCT03896711· Source

• Completed

  COVID-19 Vaccine Response in Sickle Cell Disease

  NCT05139992· Source

• Completed

  Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain

  NCT04906447· PHASE2· Source

• Completed

  A Mobile Application to Improve Procurement and Distribution of Healthful Foods & Beverages in Baltimore City

  NCT05010018· Source

• Completed

  HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

  NCT04975698· PHASE2· Source

• Completed

  Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

  NCT04770337· Source

• Completed

  Afrezza® INHALE-1 Study in Pediatrics

  NCT04974528· PHASE3· Source

• Completed

  Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

  NCT04936308· PHASE3· Source

• Completed

  PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2

  NCT04815876· Source

• Completed

  COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV

  NCT04958889· Source

• Completed

  Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

  NCT04884308· PHASE2· Source

• Completed

  Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

  NCT04864795· Source

• Recruiting

  A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

  NCT04786262· PHASE3· Source

• Completed

  PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy

  NCT04843566· Source

• Completed

  A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

  NCT04585789· PHASE2· Source

• Completed

  Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

  NCT04440592· PHASE2· Source

• Completed

  A Communication Tool to Assist Older Adults Facing Dialysis Choices

  NCT04466865· Source

• Completed

  Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis

  NCT04261790· PHASE4· Source

• Completed

  Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

  NCT04381832· PHASE1 PHASE2· Source

• Completed

  Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis

  NCT04495556· Source

• Completed

  Impact of Hypothalamic Gliosis on Appetite Regulation and Obesity Risk in Children

  NCT04260048· Source

• Completed

  EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression

  NCT04266431· Source

• Completed

  Roflumilast or Azithromycin to Prevent COPD Exacerbations Trial

  NCT04069312· PHASE3· Source

• Completed

  Bariatric Embolization of Arteries With Imaging Visible Embolics (BEATLES)

  NCT04197336· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· PHASE3· Source

• Completed

  iCLAS™ for Persistent Atrial Fibrillation

  NCT04061603· Source

• Completed

  Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

  NCT03836209· PHASE2· Source

• Completed

  Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

  NCT04259255· Source

• Completed

  ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

  NCT03622905· Source

• Completed

  Ocrelizumab Effects on the Metabolome in MS

  NCT03873389· Source

• Completed

  TRC-PAD Program: In-Clinic Trial-Ready Cohort

  NCT04004767· Source

• Completed

  Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· PHASE2· Source

• Completed

  Short-term B-cell Depletion in Relapsing Multiple Sclerosis

  NCT03853746· PHASE4· Source

Trial sites

• Johns Hopkins University249 trials
• Johns Hopkins University6 trials
• Johns Hopkins University1 trial
• Johns Hopkins University2 trials
• Johns Hopkins University1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• HIV1548 works · 16 trials
• Stroke1135 works · 8 trials
• Obesity817 works · 13 trials
• Heart failure815 works · 8 trials
• Alzheimer disease810 works · 11 trials
• Lung cancer629 works · 13 trials
• Prostate cancer542 works · 20 trials
• Type 2 diabetes502 works · 3 trials
• Chronic kidney disease460 works · 3 trials
• Tuberculosis460 works · 1 trials
• Pancreatic cancer379 works · 8 trials
• Multiple sclerosis315 works · 10 trials
• Type 1 diabetes314 works · 6 trials
• Colorectal cancer292 works · 6 trials
• Asthma292 works · 1 trials
• Atrial fibrillation280 works · 5 trials
• Coronary artery disease273 works · 9 trials
• Epilepsy273 works · 6 trials
• Melanoma270 works · 2 trials
• Parkinson disease253 works · 3 trials
• Schizophrenia227 works · 1 trials
• Glioblastoma205 works · 5 trials
• Acute myeloid leukemia191 works · 5 trials
• COPD187 works · 6 trials
• Ovarian cancer166 works · 2 trials
• Cystic fibrosis158 works · 12 trials
• Sarcoma157 works · 11 trials
• Cervical cancer149 works · 3 trials
• Sickle cell disease140 works · 5 trials
• Bipolar disorder138 works · 0 trials